1. Introduction {#sec1-marinedrugs-17-00706}
===============

Gorgonian corals belonging to the genus *Junceella* (family Ellisellidae) \[[@B1-marinedrugs-17-00706],[@B2-marinedrugs-17-00706],[@B3-marinedrugs-17-00706]\], distributed abundantly in the coral reefs of tropical Indo-Pacific Ocean have been found to produce briarane diterpenoids, natural products of a marine origin, in abundance \[[@B4-marinedrugs-17-00706]\]. In our further research into the natural products of *Junceella fragilis* (Ridley 1884) ([Figure 1](#marinedrugs-17-00706-f001){ref-type="fig"}), which was distributed extensively in the waters of Southern Taiwan, have resulted in the isolation of three new 11,20-epoxybriaranes-- fragilides U--W (**1**--**3**) along with two know compounds junceellonoid D (**4**) \[[@B5-marinedrugs-17-00706]\] and junceellin (**5**) \[[@B6-marinedrugs-17-00706],[@B7-marinedrugs-17-00706],[@B8-marinedrugs-17-00706],[@B9-marinedrugs-17-00706],[@B10-marinedrugs-17-00706],[@B11-marinedrugs-17-00706],[@B12-marinedrugs-17-00706],[@B13-marinedrugs-17-00706],[@B14-marinedrugs-17-00706],[@B15-marinedrugs-17-00706]\] ([Figure 1](#marinedrugs-17-00706-f001){ref-type="fig"}). An anti-inflammatory assay was employed to evaluate the activity of these isolates against the release of inducible nitric oxide synthase (iNOS) from macrophage cells RAW264.7.

2. Results and Discussion {#sec2-marinedrugs-17-00706}
=========================

Fragilide U (**1**) was isolated as an amorphous powder and displayed a sodiated pseudomolecular ion at *m/z* 589.22583 in the (+)-HRESIMS, which suggested that the molecular formula of **1** was C~28~H~38~O~12~ (calcd. for C~28~H~38~O~12~ + Na, 589.22555) (Ω = 10). The IR spectrum of **1** showed the presence of hydorxy (ν~max~ 3445 cm^−1^), γ-lactone (ν~max~ 1780 cm^−1^), and ester (ν~max~ 1733 cm^−1^) groups. Analysis of the ^1^H, ^13^C NMR, and distortionless enhancement by polarization transfer (DEPT) spectra together with the molecular formula, suggested that there must be an exchangeable proton. The ^13^C NMR spectrum ([Table 1](#marinedrugs-17-00706-t001){ref-type="table"}), in combination with DEPT and heteronuclear single quantum coherence (HSQC) spectra, revealed the presence of four acetoxy groups (δ~C~ 21.7, 21.2, 20.9, 20.8, 4 × CH~3~; δ~C~ 170.1, 169.8, 169.4, 169.0, 4 × C), a γ-lactone moiety (δ~C~ 175.9), and a trisubstituted olefin (δ~C~ 142.0, C; 120.6, CH). Base on the ^13^C NMR data and numbers of unsaturation, **1** was established as a diterpenoid featuring with four rings. An exocyclic epoxy group was deduced from the signals of an oxygenated quaternary carbon and an oxymethylene at δ~C~ 62.5 and 59.1, respectively, and further supported by the chemical shifts of oxymethylene protons at δ~H~ 2.85 (1H, d, *J* = 4.4 Hz) and 2.98 (1H, dd, *J* = 4.4, 1.6 Hz). Moreover, a methyl singlet (δ~H~ 1.09, 3H, s), a methyl doublet (δ~H~ 1.15, 3H, d, *J* = 7.6 Hz), a vinyl methyl (δ~H~ 2.00, 3H, d, *J* = 1.6 Hz), three pairs of aliphatic methylene protons (δ~H~ 2.04, 1H, m; 2.62, 1H, ddd, *J* = 18.4, 4.0, 2.4 Hz; 1.13, 1H, m; 2.30, 1H, m; 2.11, 1H, m; 1.81, 1H, m), two aliphatic methine protons (δ~H~ 2.36, 1H, dd, *J* = 5.6, 1.6 Hz; 2.33, 1H, q, *J* = 7.6 Hz), five oxymethine protons (δ~H~ 5.91, 1H, br s; 5.65, 1H, d, *J* = 5.6 Hz; 5.04, 1H, d, *J* = 8.8 Hz; 5.03, 1H, br s; 4.71, 1H, d, *J* = 4.8 Hz), an olefin proton (δ~H~ 5.67, 1H, dq, *J* = 8.8, 1.6 Hz), four acetate methyls (δ~H~ 2.24, 2.01, 1.99, 1.98, each 3H × s), and a hydroxy proton (δ~H~ 4.85, 1H, br s) were observed in the ^1^H NMR spectrum ([Table 2](#marinedrugs-17-00706-t002){ref-type="table"}).

Coupling information in the correlation spectroscopy (COSY) analysis enabled the proton sequences from H-2/H~2~-3/H-4, H-6/H-7, H-9/H-10, H~2~-12/H~2~-13/H-14, and H-17/H~3~-18 ([Figure 2](#marinedrugs-17-00706-f002){ref-type="fig"}), which was assembled with a heteronuclear multiple bond correlation (HMBC) experiment ([Figure 2](#marinedrugs-17-00706-f002){ref-type="fig"}). The HMBC between protons and quaternary carbons, such as H-2, H-10, H-13β, H-14, H~3~-15/C-1; H-7, H~3~-16/C-5; H-9, H-10, H~3~-18/C-8; H-9, H-10, H~2~-12, H-13α, H~2~-20/C-11; and H-17, H~3~-18/C-19, permitted elucidation of the carbon skeleton of **1**. A vinyl methyl at C-5 was confirmed by the HMBC between H~3~-16/C-4, C-5, C-6 and H-6/C-16; and further supporting by an allylic coupling between H-6 and H~3~-16 (*J* = 1.6 Hz). The methyl group on C-1 (Me-15) was substantiated by the HMBC from H~3~-15/C-1, C-2, C-10, C-14; and H-2, H-10, H-14/C-15. The epoxy group at C-11/20 was confirmed by the HMBC between H~2~-20/C-10, C-11; and H-20a/C-12; and further supporting by a long range ^4^*J*-^1^H--^1^H correlation between H-10 (δ~H~ 2.36) and H-20b (δ~H~ 2.98) (*J* = 1.6 Hz). A hydroxy group attaching at C-8 was to infer that an HMBC of a hydroxy proton at δ~H~ 4.85 to C-7, C-8, and C-9. Moreover, HMBC from the oxymethine protons at δ~H~ 5.03 (H-2), 5.65 (H-9), and 4.71 (H-14) to the acetate carbonyls at δ~C~ 169.0, 169.4, and 170.1, placed the acetoxy groups on C-2, C-9, and C-14, respectively. Ten of the 12 oxygen atoms in the molecular formula of **1** could be accounted for the presence of a γ-lactone, three esters, an epoxide, and a hydroxy group. Thus, the remaining two oxygen atoms had to be positioned at C-4 as an acetoxy group, as indicated by its ^1^H and ^13^C NMR chemical shifts (δ~H~ 5.91, 1H, br s; δ~C~ 70.6, CH), although no HMBC was observed from H-4 to any acetate carbonyl.

Based on a summary of the ^13^C chemical shifts of 11,20-epoxy group in naturally occurring briarane analogues, with ^13^C NMR data for C-11 and C-20 at δ~C~ 62--63 and 58--60 ppm, the epoxide group was β-oriented and the cyclohexane ring existed in a twist boat conformation \[[@B16-marinedrugs-17-00706]\]; thus, the configuration of the 11,20-epoxy group in **1** should be β-oriented and the cyclohexane ring was found to be in a twist boat conformation for the ^13^C chemical shifts at δ~C~ 62.5 (C-11) and 59.1 (CH~2~- 20). The relative stereochemistry of **1** was established by the analysis of correlations observed in a nuclear Overhauser effect spectroscopy (NOESY) experiment ([Figure 2](#marinedrugs-17-00706-f002){ref-type="fig"}). In the NOESY spectrum of **1**, NOE correlations between H-10/H-2, H-10/H-9, and H-10/OH-8, while no correlation was seen between H-10 and H~3~-15, suggesting that these protons H-2, H-9, and H-10, and the hydroxy group at C-8 were α-oriented; meanwhile, an NOE correlation of H~3~-15 with H-14 indicated that H-14 was β-oriented. The NOESY spectrum showed a correlation from H-6 to H~3~-16, revealing the *Z* geometry of C-5/6 double bond. H~3~-18 exhibited NOE correlations to OH-8 and H-9, suggesting the α-orientation of Me-18 at C-17. H-7 displayed NOE correlations with H-4 and H-17, which further confirmed that these three protons were in β-orientation at C-7, C-4, and C-17. Based on the above findings, the relative configurations of stereogenic carbons of **1** were elucidated as 1*R*\*,2*S*\*,4*S*\*,7*S*\*, 8*R*\*,9*S*\*,10*S*\*,11*S*\*,14*S*\* and 17*R*\*. However, as briaranes **1**--**4** were isolated along with the known chlorinated briarane, junceellin (**5**) \[[@B6-marinedrugs-17-00706]\], and the structure, including the absolute configuration of junceellin (**5**) was further confirmed by a single-crystal X-ray diffraction analysis \[[@B7-marinedrugs-17-00706],[@B15-marinedrugs-17-00706]\]. It is reasonable, therefore, on biogenetic grounds to assume that briaranes **1**--**4** have the same absolute configuration as that of **5**. Therefore, the configurations of the stereogenic carbons of **1** should be elucidated as 1*R*,2*S*,4*S*,7*S*,8*R*,9*S*,10*S*,11*S*,14*S* and 17*R* ([Supplementary Materials, Figures S1--S8](#app1-marinedrugs-17-00706){ref-type="app"}).

Our present study has also led to the isolation of a new briarane, fragilide V (**2**). The molecular formula of C~26~H~35~ClO~11~ was deduced from (+)-HRESIMS at *m/z* 581.17589 (calcd. for C~26~H~35~^35^ClO~11~ + Na, 581.17601). Carbonyl resonances in the ^13^C NMR spectrum of **2** ([Table 1](#marinedrugs-17-00706-t001){ref-type="table"}) at δ~C~ 175.2, 171.0, 170.1, and 169.7 revealed the presence of a γ-lactone and three esters. In the ^1^H NMR spectrum of **2** ([Table 2](#marinedrugs-17-00706-t002){ref-type="table"}), the signals for three acetate methyls were observed at δ~H~ 2.23, 2.03, and 1.99. It was found that the 1D ([Table 1](#marinedrugs-17-00706-t001){ref-type="table"} and [Table 2](#marinedrugs-17-00706-t002){ref-type="table"}) and 2D NMR ([Figure 3](#marinedrugs-17-00706-f003){ref-type="fig"}) data of **2** were similar to those of a known briarane, robustolide F (**6**) \[[@B17-marinedrugs-17-00706],[@B18-marinedrugs-17-00706]\] ([Figure 1](#marinedrugs-17-00706-f001){ref-type="fig"}), except that the signals corresponding to a hydroxy group in **2** were replaced by signals for a proton in **6**. In the NOESY spectrum, one of the C-3 methylene protons (δ~H~ 2.38) showed a correlation to H-7 and not with H-2, suggesting the β-orientation of this proton by modeling study and the other was assigned as H-3α (δ~H~ 1.75). A correlation from H-4 to H-3α, suggested that H-4 was α-oriented according to modeling analysis. Therefore, the configuration of the stereogenic carbons of **2** were elucidated as 1*R*,2*S*,4*R*,6*S*,7*R*,8*R*,9*S*,10*S*,11*S*,14*S,* and 17*R* ([Figure 3](#marinedrugs-17-00706-f003){ref-type="fig"}) ([Supplementary Materials, Figures S9--S16](#app1-marinedrugs-17-00706){ref-type="app"}).

Briarane **3** (fragilide W) was found to have a molecular formula of C~26~H~33~ClO~10~ based on its (+)- HRESIMS at *m/z* 563.16554 (calcd. for C~26~H~33~^35^ClO~10~ + Na, 563.16545). Its absorption peaks in the IR spectrum showed ester, γ-lactone, and broad OH stretching at 1738, 1777, and 3459 cm^−1^, respectively. The ^13^C NMR spectrum indicated that three esters and a γ-lactone were present, as carbonyl resonances were observed at δ~C~ 174.8, 170.4, 169.7, 169.3 ([Table 1](#marinedrugs-17-00706-t001){ref-type="table"}). The ^1^H NMR spectrum indicated the presence of three acetate methyls (δ~H~ 2.27, 2.25, 2.11, each 3H × s) ([Table 2](#marinedrugs-17-00706-t002){ref-type="table"}). The ^1^H and ^13^C NMR spectra of **3** was found to be similar with those of a known briarane, juncenolide M (= frajunolide S) (**7**) ([Figure 1](#marinedrugs-17-00706-f001){ref-type="fig"}), isolated from *J. juncea* and *J. fragilis* \[[@B19-marinedrugs-17-00706],[@B20-marinedrugs-17-00706]\], except that the signals corresponding to the 13-acetoxy and 3(*Z*)-ene moieties in **7** were disappeared and replaced by a proton and an (*E*)-ene moieties in **3**, respectively. The locations of the functional groups were confirmed by 2D-NMR correlations ([Figure 4](#marinedrugs-17-00706-f004){ref-type="fig"}), and hence the structure of fragilide W was assigned as **3**, and the configurations of the stereogenic carbons were elucidated as 1*R*,2*S*,7*S*,8*R*,9*S*,10*S*,11*R*, 14*S,* and 17*R* ([Figure 4](#marinedrugs-17-00706-f004){ref-type="fig"}) ([Supplementary Materials, Figures S17--S24](#app1-marinedrugs-17-00706){ref-type="app"}).

The known compound **4** was found to be identical with the known junceellonoid D, on the basis of the comparison of its physical and spectroscopic data with those of reported previously \[[@B5-marinedrugs-17-00706],[@B21-marinedrugs-17-00706]\] ([Supplementary Materials, Figures S25--S32](#app1-marinedrugs-17-00706){ref-type="app"}).

Using an *in vitro* pro-inflammatory suppression assay, the activities of briaranes **1**--**5** on the release of iNOS and cyclooxygenase-2 (COX-2) protein from lipopolysaccharides (LPS)-stimulated RAW264.7 were assayed ([Figure 5](#marinedrugs-17-00706-f005){ref-type="fig"} and [Table 3](#marinedrugs-17-00706-t003){ref-type="table"}). The results showed that briaranes **3** and **5** reduced the release of iNOS to 28.55 and 33.72% at a concentration of 10 μM. Briarane **4** was found to be more weak in terms of reducing the expression of iNOS, indicating that the activity of briaranes **4** and **5** is largely dependent on the functional groups at C-2 and C-3. It is interesting to note that briarane **4** was found to enhance the expression of COX-2 to 130.88%, at a concentration of 10 μM.

3. Materials and Methods {#sec3-marinedrugs-17-00706}
========================

3.1. General Experimental Procedures {#sec3dot1-marinedrugs-17-00706}
------------------------------------

Melting points were determined using a Fargo apparatus and the values were uncorrected. 1D and 2D NMR spectra were recorded on a 600 MHz Jeol NMR (model ECZ600R, Tokyo, Japan) or on a 400 MHz Jeol NMR (model ECZ400S) spectrometers using the residual CHCl~3~ signal (δ~H~ 7.26 ppm) and CDCl~3~ (δ~C~ 77.1 ppm) as internal standards for ^1^H and ^13^C NMR, respectively. ESIMS and HRESIMS were obtained from the Bruker mass spectrometer with 7 Tesla magnets (model: SolariX FTMS system, Bremen, Germany). Column chromatography, HPLC, IR, and optical rotation were performed according to our earlier research \[[@B15-marinedrugs-17-00706]\].

3.2. Animal Material {#sec3dot2-marinedrugs-17-00706}
--------------------

Specimens of *J. fragilis* used for this study were collected in April 2017 by self-contained underwater breathing apparatus (SCUBA) at depths of 10−15 m off the coast of South Bay, Kenting, Taiwan. The samples were stored in a −20 °C freezer until extraction. A voucher specimen was deposited in the NMMBA (voucher no.: NMMBA-TW-GC-2017-022). Identification of the species of this organism was performed by comparison as described in previous studies \[[@B1-marinedrugs-17-00706],[@B2-marinedrugs-17-00706],[@B3-marinedrugs-17-00706]\].

3.3. Extraction and Isolation {#sec3dot3-marinedrugs-17-00706}
-----------------------------

Sliced bodies (wet/dry weight = 795/313 g) of the coral specimen were prepared and extracted with a 1:1 mixture of methanol (MeOH) and dichloromethane (CH~2~Cl~2~) (1:1) to give a crude extract (19.0 g) which was partitioned between ethyl acetate (EtOAc) and H~2~O. The EtOAc extract (8.0 g) was then applied to a silica gel column chromatograph (C.C.) and eluted with gradients of *n*- hexane/acetone (stepwise from 50:1 to 1:2; volume ratio) to furnish 8 fractions (fractions: A−H). Fraction F was chromatographed on silica gel C.C. and eluted with gradients of *n*-hexane/EtOAc (2:1 to 1:2, stepwise) to furnish 4 fractions (fractions F1−F4). Fraction F3 was washed with a mixture of *n*-hexane/acetone (30:1) and the undissolved **5** (23.5 mg) was obtained. Fraction G was purified by normal-phase HPLC (NP-HPLC) using a mixture of *n*-hexane and EtOAc (4:1 to 1:1, stepwise) to afford 16 fractions (fractions G1−G16). Afterward, fraction G15 was separated by NP-HPLC using a mixture of CH~2~Cl~2~ and acetone (v:v = 10:1; at a flow rate = 2.0 mL/min) to yield **1** (1.7 mg). Fraction G14 was separated by NP-HPLC using a mixture of *n*-hexane/acetone (2:1; volume ratio) to yield 6 fractions (fractions: G14A−G14F). Fractions G14C and G14D were combined and purified by reverse-phase HPLC (RP-HPLC) using a mixture of MeOH and H~2~O (v:v = 65:35; at a flow rate = 4.0 mL/min) to afford **2** (0.8 mg). Fraction G9 was purified by RP-HPLC using a mixture of MeOH and H~2~O (v:v = 60:40; at a flow rate = 4.0 mL/min) to yield 16 fractions (fractions G9A−G9P), including compound **3** (0.8 mg, G9D). Fraction G9M was separated by RP-HPLC using a mixture of acetonitrile and H~2~O (v:v = 55:45; at a flow rate = 4.0 mL/min) to obtain **4** (0.8 mg).

Fragilide U (**1**): Amorphous powder; $\left\lbrack \mathsf{\alpha} \right\rbrack_{D}^{24}$ −12 (*c* 0.09, CHCl~3~); IR (KBr) ν~max~ 3445, 1780, 1733 cm^−1^; ^13^C (100 MHz, CDCl~3~) and ^1^H (400 MHz, CDCl~3~) NMR data, see [Table 1](#marinedrugs-17-00706-t001){ref-type="table"}; [Table 2](#marinedrugs-17-00706-t002){ref-type="table"}; ESIMS: *m/z* 589 \[M + Na\]^+^; HRESIMS: *m/z* 589.22583 (calcd. for C~28~H~38~O~12~ + Na, 589.22555).

Fragilide V (**2**): Amorphous powder; $\left\lbrack \mathsf{\alpha} \right\rbrack_{D}^{23}$ −26 (*c* 0.04, CHCl~3~); IR (KBr) ν~max~ 3444, 1779, 1738 cm^−1^; ^13^C (100 MHz, CDCl~3~) and ^1^H (400 MHz, CDCl~3~) NMR data, see [Table 1](#marinedrugs-17-00706-t001){ref-type="table"}; [Table 2](#marinedrugs-17-00706-t002){ref-type="table"}; ESIMS: *m/z* 581 \[M + Na\]^+^, 583 \[M + 2 + Na\]^+^; HRESIMS: *m/z* 581.17589 (calcd. for C~26~H~35~^35^ClO~11~ + Na, 581.17601).

Fragilide W (**3**): Amorphous powder; $\left\lbrack \mathsf{\alpha} \right\rbrack_{D}^{23}$ −21 (*c* 0.04, CHCl~3~); IR (KBr) ν~max~ 3459, 1777, 1738 cm^−1^; ^13^C (150 MHz, CDCl~3~) and ^1^H (600 MHz, CDCl~3~) NMR data, see [Table 1](#marinedrugs-17-00706-t001){ref-type="table"}; [Table 2](#marinedrugs-17-00706-t002){ref-type="table"}; ESIMS: *m/z* 563 \[M + Na\]^+^, 565 \[M + 2 + Na\]^+^; HRESIMS: *m/z* 563.16554 (calcd. for C~26~H~33~^35^ClO~10~ + Na, 563.16545).

Junceellonoid D (**4**): Amorphous powder; $\left\lbrack \mathsf{\alpha} \right\rbrack_{D}^{24}$ −18 (*c* 0.04, CHCl~3~) (ref. \[[@B5-marinedrugs-17-00706]\] $\left\lbrack \mathsf{\alpha} \right\rbrack_{D}^{~}$ −44.8 (*c* 0.10, CHCl~3~, MeOH); ref. \[[@B21-marinedrugs-17-00706]\] $\left\lbrack \mathsf{\alpha} \right\rbrack_{D}^{23}$ −31 (*c* 0.05, CHCl~3~)); IR (ATR) ν~max~ 3509, 1793, 1733 cm^−1^; ^13^C and ^1^H NMR data were found to be in full agreement with those reported previously \[[@B21-marinedrugs-17-00706]\]; ESIMS: *m/z* 521 \[M + Na\]^+^, 523 \[M + 2 + Na\]^+^; HRESIMS: *m/z* 521.15469 (calcd. for C~24~H~31~^35^ClO~9~ + Na, 521.15488).

Junceellin (**5**): Colorless crystals; mp 277--278 °C (ref. \[[@B15-marinedrugs-17-00706]\] mp 272--275 °C); $\left\lbrack \mathsf{\alpha} \right\rbrack_{D}^{23}$ −3 (*c* 1.18, CHCl~3~) (ref. \[[@B15-marinedrugs-17-00706]\] $\left\lbrack \mathsf{\alpha} \right\rbrack_{D}^{25}$ −2 (*c* 0.89, CHCl~3~)); IR (KBr) ν~max~ 1794, 1743 cm^−1^; ^13^C and ^1^H NMR data were found to be in full agreement with those reported previously \[[@B6-marinedrugs-17-00706],[@B8-marinedrugs-17-00706],[@B9-marinedrugs-17-00706],[@B12-marinedrugs-17-00706]\]; ESIMS: *m/z* 605 \[M + Na\]^+^, 607 \[M + 2 + Na\]^+^; HRESIMS: *m/z* 605.17612 (calcd. for C~28~H~35~^35^ClO~11~ + Na, 605.17601).

3.4. In Vitro Anti-Inflammatory Assay {#sec3dot4-marinedrugs-17-00706}
-------------------------------------

The anti-inflammatory assay was employed to evaluate the activities of briaranes **1**--**5** reduce the release of iNOS and COX-2 from macrophage cells as the literature reported \[[@B22-marinedrugs-17-00706],[@B23-marinedrugs-17-00706],[@B24-marinedrugs-17-00706],[@B25-marinedrugs-17-00706]\].

4. Conclusions {#sec4-marinedrugs-17-00706}
==============

*J. fragilis* was proven to be a rich source to produce a wide structural diversity of briarane-type diterpenoids that possess various biomedical properties, particularly in anti-inflammatory activity \[[@B26-marinedrugs-17-00706],[@B27-marinedrugs-17-00706]\]. In our continued study on *J. fragilis*, three previously unreported 11,20-epoxybriaranes, fragilides U--W (**1**--**3**), along with two known briaranes, junceellonoid D (**4**) and junceellin (**5**), were isolated. The exocyclic 11,20-epoxy group was proven to be a chemical marker for briarane-type natural products from the gorgonian corals belonging to the family Ellisellidae \[[@B28-marinedrugs-17-00706]\]. In the present study, the anti-inflammatory activity of **1**--**5** was assayed using inhibition of iNOS and COX-2 and the results indicated that fragilide W (**3**) and junceellin (**5**) showed the most potent suppressive effect on iNOS release.

The Supplementary Materials are available online at <https://www.mdpi.com/1660-3397/17/12/706/s1>. HRESIMS, IR, 1D and 2D NMR spectra of compounds **1**--**4**.
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![Activities of briaranes **1**--**5** on the expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) proteins in LPS-treated murine RAW264.7 macrophage cells. Western blotting showed that briaranes **3** and **5** reduced the expression of iNOS. Data were normalized to the cells treated with LPS only, and cells treated with dexamethasone were used as a positive control. Data are expressed as the mean ± SEM (*n* = 3). \* Significantly different from cells treated with LPS (*p* \< 0.05).](marinedrugs-17-00706-g005){#marinedrugs-17-00706-f005}
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^13^C NMR data for briaranes **1**--**3**.

  Position            1 ^a^         2 ^a^          3 ^b^
  ------------------- ------------- -------------- -------------
  1                   47.0, C ^c^   46.1, C        49.1, C
  2                   72.2, CH      72.1, CH       75.4, CH
  3                   37.5, CH~2~   37.6, CH~2~    136.4, CH
  4                   70.6, CH      73.4, CH       128.2, CH
  5                   142.0, C      144.1, C       135.9, C
  6                   120.6, CH     58.0, CH       128.8, CH
  7                   76.5, CH      79.0, CH       80.0, CH
  8                   80.4, C       81.9, C        80.9, C
  9                   67.4, CH      68.9, CH       67.1, CH
  10                  39.9, CH      39.8, CH       39.5, CH
  11                  62.5, C       62.6, C        60.8, C
  12                  23.6, CH~2~   23.5, CH~2~    29.4, CH~2~
  13                  24.2, CH~2~   24.0, CH~2~    25.5, CH~2~
  14                  73.2, CH      73.5, CH       78.9, CH
  15                  14.6, CH~3~   15.4, CH~3~    16.0, CH~3~
  16                  21.4, CH~3~   121.0, CH~2~   48.0, CH~2~
  17                  42.4, CH      43.8, CH       45.2, CH
  18                  6.6, CH~3~    7.1, CH~3~     6.9, CH~3~
  19                  175.9, C      175.2, C       174.8, C
  20                  59.1, CH~2~   58.2, CH~2~    50.4, CH~2~
  Acetate methyls     21.7, CH~3~   21.9, CH~3~    21.7, CH~3~
                      21.2, CH~3~   21.0, CH~3~    21.4, CH~3~
                      20.9, CH~3~   21.0, CH~3~    21.3, CH~3~
                      20.8, CH~3~                  
  Acetate carbonyls   170.1, C      171.0, C       170.4, C
                      169.8, C      170.1, C       169.7, C
                      169.4, C      169.7, C       169.3, C
                      169.0, C                     

^a^ Spectra measured at 100 MHz in CDCl~3~. ^b^ Spectra measured at 150 MHz in CDCl~3~. ^c^ Multiplicity deduced by distortionless enhancement by polarization transfer (DEPT) and heteronuclear single quantum coherence (HSQC) spectra.
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###### 

^1^H NMR data (*J* in Hz) for briaranes **1**--**3**.

  Position          1 ^a^                               2 ^a^                           3 ^b^
  ----------------- ----------------------------------- ------------------------------- ------------------------------------------
  2                 5.03 br s                           4.96 dd (2.8, 2.8)              5.63 d (6.0)
  3α/β              2.04 m; 2.62 ddd (18.4, 4.0, 2.4)   1.75 m; 2.38 m                  6.04 dd (17.4, 6.0)
  4                 5.91 br s                           4.85 m                          6.42 d (17.4)
  6                 5.67 dq (8.8, 1.6)                  5.49 br s                       5.66 d (3.6)
  7                 5.04 d (8.8)                        5.15 d (2.4)                    5.62 d (3.6)
  9                 5.65 d (5.6)                        5.52 d (6.4)                    4.77 d (6.6)
  10                2.36 dd (5.6, 1.6)                  2.31 d (6.4)                    3.32 d (6.6)
  12α/β             1.13 m; 2.30 m                      1.15 m; 2.30 m                  1.29 m; 2.18 m
  13α/β             2.11 m; 1.81 m                      2.14 m; 1.78 m                  2.08 m; 1.85 dddd (12.0, 12.0, 3.6, 1.8)
  14                4.71 d (4.8)                        4.86 d (4.4)                    4.94 dd (3.6, 3.0)
  15                1.09 s                              1.13 s                          0.87 s
  16a/b             2.00 d (1.6)                        5.74 s; 5.97 s                  4.13 d (12.0); 4.19 d (12.0)
  17                2.33 q (7.6)                        2.29 q (7.6)                    2.36 q (7.2)
  18                1.15 d (7.6)                        1.22 d (7.6)                    1.18 d (7.2)
  20a/b             2.85 d (4.4); 2.98 dd (4.4, 1.6)    2.83 d (4.0); 2.85 br d (4.0)   2.76 d (2.4); 3.40 dd (2.4, 2.4)
  OH-8              4.85 br s                           4.63 br s                       3.13 d (1.2)
  Acetate methyls   2.24 s                              2.23 s                          2.27 s
                    2.01 s                              2.03 s                          2.25 s
                    1.99 s                              1.99 s                          2.11 s
                    1.98 s                                                              

^a^ Spectra measured at 400 MHz in CDCl~3~. ^b^ Spectra measured at 600 MHz in CDCl~3~.
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###### 

Effects of briaranes **1**--**5** on LPS-induced pro-inflammatory inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) protein expression in macrophages at a concentration of 10 μM.

                        iNOS             COX-2            β-Actin
  --------------------- ---------------- ---------------- ---------------
  Lipopolysaccharides   100.01 ± 17.81   100.00 ± 3.04    100.00 ± 6.05
  1                     55.88 ± 11.42    64.73 ± 4.07     90.05 ± 7.11
  2                     77.58 ± 8.82     66.23 ± 6.59     99.29 ± 5.24
  3                     28.55 ± 5.35     86.46 ± 8.46     101.69 ± 6.46
  4                     67.25 ± 4.27     130.88 ± 13.94   103.20 ± 2.56
  5                     33.72 ± 2.57     64.15 ± 3.03     84.52 ± 7.78
  Dexamethasone         12.11 ± 0.03     2.11 ± 0.44      123.86 ± 2.99

Data were normalized to those of cells treated with LPS alone, and cells treated with dexamethasone were used as a positive control (10 μM). Data are expressed as the mean ± SEM (*n* = 3).

[^1]: These authors contributed equally to this work.
